Healthcare [ 3/11 ] | Biotechnology [ 38/157 ]
CA | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Mar 23, 23 | -0.11
Increased by
+59.26%
|
-0.11 |
Nov 1, 22 | -0.11
Increased by
+15.38%
|
-0.12
Increased by
+69.44%
|
Aug 2, 22 | -0.11
Increased by
+26.67%
|
-0.13
Increased by
+118.34%
|
May 9, 22 | -0.12
Increased by
+25.00%
|
-0.15
Increased by
+133.33%
|
Mar 22, 22 | -0.27
Decreased by
-80.00%
|
-0.17
Decreased by
-346.02%
|
Nov 11, 21 | -0.13
Increased by
+38.10%
|
-0.17
Increased by
+138.41%
|
Aug 3, 21 | -0.15
Increased by
0.00%
|
-0.19
Increased by
+110.80%
|
Mar 23, 21 | -0.16
Decreased by
-23.08%
|
-0.17
Increased by
+34.60%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-9.78 M
Increased by
+13.73%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-10.56 M
Increased by
+21.57%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-11.48 M
Increased by
+29.25%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
N/A%
|
-24.32 M
Decreased by
-65.32%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-11.33 M
Increased by
+14.46%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
N/A%
|
-13.47 M
Increased by
+14.48%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 21 | 0.00
Decreased by
N/A%
|
-16.23 M
Decreased by
-40.79%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 20 | 0.00
Decreased by
N/A%
|
-14.71 M
Decreased by
-90.85%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.